An image of the Charlotte R. Bloomberg Children's Center and Sheikh Zayed Tower
 
 

Roger A. Johns, MD, MHS

Roger A. Johns, MD, MHS

The Mark C. Rogers Professor, 1999-2003

Professor
Department of Anesthesiology and Critical Care Medicine
The Johns Hopkins University School of Medicine
Sheikh Zayed Tower
1800 Orleans Street
Baltimore, MD 21287

Phone: 410-614-1810

Dr. Roger Johns, a clinician-scientist who specializes in cardio-thoracic anesthesia, has a multitude of interests and is equally enthusiastic about each. He began his scientific career in the race to discover the identity of “Endothelium-Derived Relaxing Factor” or EDRF, which proved to be nitric oxide. This small, unassuming molecule (NO) has led him in a pursuit of the mechanisms underlying anesthesia, analgesia, pain, and lung vascular biology. Discoveries include the regulation of NO production by high and low oxygen concentrations and NO’s role in lung biology, including pulmonary hypertension, ciliary motility, development, and transition of the fetal pulmonary circulation. Dr. Johns and his group discovered the role of the NO pathway in mechanisms of anesthesia and have published important work implicating this pathway in the mechanism of plasticity associated with chronic inflammatory and neuropathic pain.

In one of Dr. Johns’ current projects, he and his team are investigating the molecular mechanisms that underlie the onset and maintenance of chronic pain, particularly neuropathic pain. This research has helped to elucidate a vast network of molecules at neuronal synapses, particularly the post-synaptic density (PSD), that are critical for pain signal propagation. Within the PSD, Dr. Johns’ focus is on small molecular scaffolding proteins, such as PSD-95 and PSD-93, that help to regulate trafficking of receptors (e.g., NMDA, AMPA). Importantly, these scaffolding proteins link these receptors to their downstream signaling pathways that include enzymes such as NO synthase, guanylyl cyclase, and protein kinase G. This work includes the development of new analgesics to interfere with the PSD protein interactions in the hopes of providing relief for those who suffer from debilitating chronic pain.

Another of Dr. Johns’ interests is in the mechanism of inhalational anesthetics, such as the commonly used sevoflurane. Although anesthetics have been used for surgery for at least 150 years, surprisingly, their mechanism of action is not understood. This part of his lab group is focused on the ability of these anesthetics to specifically disrupt critical protein-protein interactions that mediate excitatory neurotransmission and contribute to the anesthetic state.

Recently, Dr. Johns and his team identified a gene that was highly upregulated in a hypoxia-induced model of pulmonary hypertension and named it hypoxia-induced mitogenic factor (HIMF). They found that the HIMF protein is upregulated by hypoxia and by TH2 stimulation and that it is expressed in the remodeling pulmonary vessels. They also showed that recombinant HIMF has mitogenic, angiogenic, vasoconstricting, and chemokine-like properties in lung. They have now proven a role for HIMF as a pleiotropic cytokine that mediates the vascular remodeling and induced hemodynamic changes of hypoxia-induced pulmonary hypertension. HIMF is also upregulated in some human forms of pulmonary hypertension and asthma. Large-scale human genomic and gene polymorphism studies are underway. HIMF is a member of the FIZZ/resistin/RELMbeta family of proteins, which have adipokine and insulin resistance properties, suggesting that HIMF may mediate vascular pathology associated with obesity and metabolic syndrome. Much work is still required to clarify the exact role of HIMF, but it could be a key player in inflammatory lung diseases such as pulmonary hypertension and asthma.

Dr. Johns also has an interest in health policy. He is a Robert Wood Johnson Health Policy Fellow of the Institute of Medicine, National Academy of Sciences (2005–2008) and served as a health and science policy advisor in the US Senate 109th Congress. Current policy research interests and experience include approaches to coverage decisions for new technologies and pharmaceuticals, the impact of an aging population on health systems funded through pay-as-you-go social insurance, health information technology, and the science and politics of biogeneric drugs.

Dr. Johns has trained more than 30 students and fellows now in independent academic and industrial research positions around the world. He has been continuously funded by the National Institutes of Health for over 20 years.

Download CV Adobe PDF

Learn more about Dr. Roger Johns

Dr. Roger Johns's Research bio

Learn more about Biomedical Research

 
 

Grand Rounds
Calendar and Webcasts

Grand Rounds take place Thursdays at 7 AM in Hurd Hall.

9/18: "Biological Targets For The Treatment Of Traumatic Brain Injury" – Courtney Robertson, MD
Watch webcast >>

9/25: Quality Assurance Committee Meeting

10/2: "Patient And Family-Centered Approach To Advance Care Planning" – Rebecca Aslakson, MD, PhD

10/9: Patient-Based Learning Discussion – Tracey Smith Stierer, MD

Eighth Robert A. Abraham, MD Endowed Lecture: "Post-Cesarean Pain Management: Past, Present, and Future" – Brendan Carvalho, MBBCh, FRCA, MDCH
Watch webcast >>
Learn more about Robert A. Abraham, MD >>

"ACCM - Innovation in Academic Medicine" – Mark Rogers, MD
Watch webcast >>

Combined Multidisciplinary Grand Rounds with Department of Surgery – "Perioperative Services Initiatives: Reducing Risk and Improving Outcomes"
Watch webcast >>

Archived webcasts >>

 

Out of State and International Patients

Make a Gift

 

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System, All rights reserved.

Legal Disclaimer